Characteristics | Patients with RA | Healthy Controls | p |
---|---|---|---|
N | 112 | 412 | — |
Age, yrs | 55.9 (12.6) | 48.0 (16.0) | < 0.0001 |
Female, n (%) | 57 (51) | 218 (52) | 0.70 |
White, n (%) | 66 (59) | 241 (59) | 0.93 |
Black, n (%) | 37 (33) | 171 (42) | 0.10 |
BMI, kg/m2 | 28.7 (7.2) | 26.0 (5.2) | < 0.001 |
Obese, n (%) | 41 (37) | 75 (18) | < 0.001 |
25(OH)D, ng/ml | 29.1 (14.0) | 24.7 (12.0) | 0.001 |
RA disease characteristics | |||
DAS28(CRP) | 4.07 (1.27) | — | |
HAQ score (0–3.0) | 0.79 (0.63) | — | |
ACPA-positive, n (%) | 92 (82) | — | |
SvdH score | 13.5 (3–56.5) | — | |
Disease duration, yrs | 7.6 (2.6–17.6) | — | |
Current methotrexate, n (%) | 75 (67) | — | |
Current biologic therapy, n (%) | 57 (51) | — | |
Current prednisone, n (%) | 50 (45) | — | |
Ever methotrexate, n (%) | 95 (87) | — | |
Ever biologic therapy, n (%) | 74 (66) | — | |
Ever prednisone, n (%) | 87 (78) | — | |
Current bisphosphonate | 8 (7) | — | |
Ever bisphosphonate | 18 (16) |
Results displayed as mean (SD), median (IQR) for skewed data, or n (%) for dichotomous data. RA: rheumatoid arthritis; DAS28(CRP): Disease Activity Score of 28 joints including C-reactive protein; HAQ: Health Assessment Questionnaire; ACPA: anticitrullinated peptide antibody; 25(OH) D: 25-hydroxy vitamin D; BMI: body mass index; SvdH score: Sharp/van der Heijde scoring system.